Drug
Cladribine clinical trials
Also written Leustatin, 2-CdA, RWJ-26251 and Litak.
- studies test it
- 91
- open now
- 18
- in phase 3
- 17
- first study started
- 1994
Keep track of what changes. Save the Cladribine studies recruiting or about to start, and get an email each week — studies that open, close, add sites or post results.
Watch these studiesHow studies write it
Studies that test it under each name
Name
Development codes
Combined with it in one product
Studies by the year they started
90 studies that test it; most in 2021 (10); 1 more planned to start later
| Year | Studies |
|---|---|
| 1994 | 1 |
| 1996 | 1 |
| 1997 | 1 |
| 1998 | 3 |
| 1999 | 1 |
| 2002 | 2 |
| 2003 | 2 |
| 2004 | 5 |
| 2005 | 2 |
| 2006 | 1 |
| 2008 | 6 |
| 2009 | 3 |
| 2010 | 2 |
| 2011 | 1 |
| 2012 | 2 |
| 2014 | 5 |
| 2016 | 9 |
| 2017 | 2 |
| 2018 | 7 |
| 2019 | 5 |
| 2020 | 5 |
| 2021 | 10 |
| 2022 | 7 |
| 2023 | 2 |
| 2025 | 3 |
| 2026 | 2 |
By phase
A phase 1/2 study counts in both.
- Phase 1
- 25
- Phase 2
- 55
- Phase 3
- 17
- Phase 4
- 9
- No phase
- 2
What it is tested for
Each study’s main condition, where its own words name it.
Who runs them
Industry 11 · Other 80
M.D. Anderson Cancer Center (15) · Fred Hutchinson Cancer Center (5) · University of Washington (5) · Merck KGaA, Darmstadt, Germany (4) · EMD Serono Research & Development Institute, Inc. (3) · Alliance for Clinical Trials in Oncology (3) · Sichuan University (3) · Sun Yat-sen University (3)
Often tested with
Tested in the same studies.
Cytarabine (36) · Mitoxantrone (15) · Rituximab (14) · Filgrastim (12) · Venetoclax (9) · Idarubicin (8) · Granulocyte Colony-Stimulating Factor (5) · Decitabine (5)
Studies
Open first, then newest update. How each study uses Cladribine is read from its arms, and is right about nine times in ten.
Testing it · 91
- The HIt HArd and hiT Early in Multiple Sclerosis TrialRecruitingPhase 2Uppsala UniversityNCT07517185Written as Sequential treatment with rituximab and cladribine
- Venetoclax, Cladribine, Low Dose Cytarabine, and Azacitidine in Treating Patients With Previously Untreated Acute Myeloid LeukemiaRecruitingPhase 2M.D. Anderson Cancer CenterNCT03586609Written as Cladribine
- CLAG-M or FLAG-Ida Chemotherapy and Reduced-Intensity Conditioning Donor Stem Cell Transplant for the Treatment of Relapsed or Refractory Acute Myeloid Leukemia, Myelodysplastic Syndrome, or Chronic Myelomonocytic LeukemiaRecruitingPhase 1Fred Hutchinson Cancer CenterNCT04375631Written as Cladribine
- Venetoclax in Combination With Cladribine and Cytarabine Alternating With Azacitidine Plus Venetoclax for the Treatment of Newly Diagnosed Monocytic AML and Active Signaling Mutated AMLRecruitingPhase 2OHSU Knight Cancer InstituteNCT06504459Written as Cladribine
- A Phase 1 Open-Label, Dose-Ranging Safety and Pharmacokinetics Study of Oral Cladribine in Patients With Acute Myeloid Leukemia (AML)Not yet recruitingPhase 1/2M.D. Anderson Cancer CenterNCT07053020Written as Oral Cladribine
- Phase Ib/II Trial of Cladribine/Ruxolitinib/Venetoclax in Patients With Relapsed/Refractory T-cell Prolymphocytic LeukemiaRecruitingPhase 1/2M.D. Anderson Cancer CenterNCT07311746Written as Cladribine
- Cladribine Plus Low Dose Cytarabine (LDAC) Alternating With Decitabine in Patients With Acute Myeloid Leukemia (AML) or High-Risk Myelodysplastic Syndrome (MDS)RecruitingPhase 2M.D. Anderson Cancer CenterNCT01515527Written as Cladribine
- Cladribine, Idarubicin, Cytarabine, and Quizartinib in Treating Patients With Newly Diagnosed, Relapsed, or Refractory Acute Myeloid Leukemia or High-Risk Myelodysplastic SyndromeRecruitingPhase 1/2M.D. Anderson Cancer CenterNCT04047641Written as Cladribine
- Cladribine and Rituximab in Treating Patients With Hairy Cell LeukemiaRecruitingPhase 2M.D. Anderson Cancer CenterNCT00412594Written as Cladribine
- A Phase II Study of Cladribine and Low Dose Cytarabine in Combination With Venetoclax, Alternating With Azacitidine and Venetoclax, in Patients With Higher-risk Myeloproliferative Chronic Myelomonocytic Leukemia or Higher-risk Myelodysplastic Syndromes With Excess BlastsRecruitingPhase 2M.D. Anderson Cancer CenterNCT05365035Written as Cladribine
- Cladribine, Idarubicin, Cytarabine, and Venetoclax in Treating Patients With Acute Myeloid Leukemia, High-Risk Myelodysplastic Syndrome, or Blastic Phase Chronic Myeloid LeukemiaRecruitingPhase 2M.D. Anderson Cancer CenterNCT02115295Written as Cladribine
- Venetoclax and CLAG-M for the Treatment of Acute Myeloid Leukemia and High-Grade Myeloid NeoplasmsRecruitingPhase 1/2University of WashingtonNCT04797767Written as Cladribine
- CAV Regimen for R/R Ph- B-ALLRecruitingNot applicableThe First Affiliated Hospital of Soochow UniversityNCT05657652Written as cladribine, cytarabine,venetoclax
- Therapy Optimisation for the Treatment of Hairy Cell LeukemiaRecruitingPhase 2/3University of GiessenNCT02131753Written as Cladribine s.c. injection, HCL treatment
- Cladribine vs Placebo for Non-active Progressive Multiple Sclerosis (CLASP-MS).RecruitingPhase 2/3Institute of Psychiatry and Neurology, WarsawNCT05961644Written as Cladribine Subcutaneous Injection
- Treateament of Newly Diagnosed Acute Monocytic Leukemia in ChildrenRecruitingPhase 2/3Sun Yat-Sen Memorial Hospital of Sun Yat-Sen UniversityNCT05313958Written as Cladribine
- ChiCGB vs BEAM in High-risk or R/R LymphomasRecruitingPhase 3Sichuan UniversityNCT05466318Written as Cladribine
- A Prospective Biomarker Study in Active SPMS Subjects Treated With Cladribine TabletsRecruitingPhase 4Keith Edwards, M.D.NCT04550455Written as Cladribine Tablets
- Efficacy and Pharmacogenomics of Cladribine Based Salvage Chemotherapy in Patients With Relapse/Refractory and Secondary Acute Myeloid Leukemia (AML) and High Risk Myelodysplastic Syndrome (MDS)TerminatedPhase 2Medical College of WisconsinNCT03150004Written as Cladribine and Cytarabine (CLLDAC) Regimen
- Venetoclax and Sequential Busulfan, Cladribine, and Fludarabine Phosphate Before Donor Stem Cell Transplant in Treating Patients With Acute Myelogenous Leukemia or Myelodysplastic SyndromeActive, not recruitingPhase 2M.D. Anderson Cancer CenterNCT02250937Written as Cladribine
See all 91 studies that test Cladribine →
Given in every arm · 11 — Cladribine is usual care beside what is tested
- Olutasidenib Combined With Co-targeted Therapy in Relapsed or Refractory IDH1-mutated Myeloid Malignancies Harboring Activated Signaling Pathway MutationsRecruitingPhase 2M.D. Anderson Cancer CenterNCT07032727Written as Cladribine (CLAD)
- Venetoclax to Improve Outcomes of Fractionated Busulfan Regimen in Patients With High-Risk AML and MDSRecruitingPhase 2/3M.D. Anderson Cancer CenterNCT04708054Written as Cladribine
- Dexrazoxane Hydrochloride in Preventing Heart-Related Side Effects of Chemotherapy in Participants With Blood CancersRecruitingPhase 2M.D. Anderson Cancer CenterNCT03589729Written as Cladribine
- Tagraxofusp and Low-Intensity Chemotherapy for CD123-Positive Relapsed or Refractory AMLRecruitingPhase 1/2Stanford UniversityNCT06561152Written as Cladribine (CLAD)
- CLAG+VEN vs CLAG in the Treatment of Relapsed/Refractory AMLNot yet recruitingPhase 4Nanfang Hospital, Southern Medical UniversityNCT06763666Written as Cladribine
- Cladribine Venetoclax in Monocytic AMLActive, not recruitingPhase 2University of Colorado, DenverNCT06232655Written as Cladribine
- Venetoclax-Navitoclax With Cladribine-based Salvage Therapy in Patients With Relapsed/Refractory Acute Myeloid LeukemiaWithdrawnPhase 1Medical College of WisconsinNCT06007911Written as Cladribine
- Treatment of Relapsed T-cell Acute Lymphoblastic Leukemia or T-lymphoblastic Lymphoma With MabCampathCompletedPhase 2Goethe UniversityNCT00199030Written as Cladribine
- Study of CLAG + Selinexor in Relapsed or Refractory Acute Myeloid LeukemiaCompletedPhase 1/2Washington University School of MedicineNCT02416908Written as Cladribine
- R-2cda and Prolongation of Therapy With Rituximab Alone in Chronic Lymphocytic Leukaemia and Small Lymphocytic LymphomaTerminatedPhase 2European Institute of OncologyNCT01446900Written as Cladribine
- Peripheral Stem Cell Transplantation Plus Filgrastim in Treating Patients With Acute or Chronic Myelogenous LeukemiaCompletedPhase 2M.D. Anderson Cancer CenterNCT00002833Written as Cladribine
As the comparator · 4 — what is tested is compared with Cladribine
- A Study of Vemurafenib and Obinutuzumab Compared to Cladribine and Rituximab in People With Hairy Cell Leukemia (HCL)RecruitingPhase 2Memorial Sloan Kettering Cancer CenterNCT06561360Written as Cladribine
- Testing the Combination of Anti-cancer Drugs, Tovorafenib Plus Rituximab, in Patients With Hairy Cell LeukemiaRecruitingPhase 1/2National Cancer Institute (NCI)NCT06965114Written as Cladribine
- Trial of DFP-10917 vs Non-Intensive or Intensive Reinduction for AML Patients in 2nd/3rd/4th SalvageTerminatedPhase 3Delta-Fly Pharma, Inc.NCT03926624Written as Cladribine
- Randomized Autologous heMatopoietic Stem Cell Transplantation Versus Alemtuzumab, Cladribine or Ocrelizumab for RRMS (RAM-MS)Active, not recruitingPhase 3Haukeland University HospitalNCT03477500Written as Cladribine Pill
Codes
What other systems call Cladribine · ClinicalTrials.gg INT008593
- MeSH (NLM) D017338CladribineConfirmed ClinicalTrials.gov, NLM, Wikidata
- UNII (FDA) 47M74X9YT5CLADRIBINEConfirmed FDA, NLM, Wikidata
- RxNorm 44157Confirmed FDA, Wikidata
- Wikidata Q414030cladribineConfirmed FDA, NLM, Wikidata
- NCI Thesaurus C1336CladribineConfirmed FDA, Wikidata
- DrugBank DB00242One source Wikidata
| System | Code | Name there | Checked by |
|---|---|---|---|
| MeSH (NLM) | D017338 | Cladribine | Confirmed ClinicalTrials.gov, NLM, Wikidata |
| UNII (FDA) | 47M74X9YT5 | CLADRIBINE | Confirmed FDA, NLM, Wikidata |
| RxNorm | 44157 | — | Confirmed FDA, Wikidata |
| Wikidata | Q414030 | cladribine | Confirmed FDA, NLM, Wikidata |
| NCI Thesaurus | C1336 | Cladribine | Confirmed FDA, Wikidata |
| DrugBank | DB00242 | — | One source Wikidata |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.